These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 7776946)
21. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents. Teitelbaum R; Cohen M Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990 [No Abstract] [Full Text] [Related]
22. Patents for critical pharmaceuticals: the AZT case. Ackiron E Am J Law Med; 1991; 17(1-2):145-80. PubMed ID: 1877607 [TBL] [Abstract][Full Text] [Related]
23. Pharmaceutical patent settlements: the antitrust risks. Balto DA Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464 [No Abstract] [Full Text] [Related]
24. Pharmaceutical patent life-cycle management after KSR v. Teleflex. Furrow ME Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462 [No Abstract] [Full Text] [Related]
25. Prescription drug pushers. Patents and ads are the big reasons pills are priced like perfume and caviar. Sherrid P US News World Rep; 2000 Oct; 129(17):40-2. PubMed ID: 11184929 [No Abstract] [Full Text] [Related]
26. Funding pharmaceutical innovation through direct tax credits. Lybecker KM; Freeman RA Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650 [TBL] [Abstract][Full Text] [Related]
28. America's other drug problem: how the drug industry distorts medicine and politics. Relman AS; Angell M New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803 [No Abstract] [Full Text] [Related]
29. NIH urged to cap profits made on publicly funded research. Macilwain C Nature; 2000 Jul; 406(6791):5. PubMed ID: 10894508 [No Abstract] [Full Text] [Related]
30. Using market-exclusivity incentives to promote pharmaceutical innovation. Kesselheim AS N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231 [No Abstract] [Full Text] [Related]
32. Medicine. The intangible value of vaccination. Rappuoli R; Miller HI; Falkow S Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712 [No Abstract] [Full Text] [Related]
33. Not taking, just borrowing: government use of patented drugs. Ossorio PN Am J Bioeth; 2002; 2(3):51-2. PubMed ID: 12230861 [No Abstract] [Full Text] [Related]
36. The Dunkel draft--a prescription for disaster. George T; Amalorpavanathan J; Begum Z Natl Med J India; 1992; 5(4):153-4. PubMed ID: 1304298 [No Abstract] [Full Text] [Related]
37. Patent watch. Harrison C Nat Rev Drug Discov; 2008 Nov; 7(11):882-3. PubMed ID: 18974746 [No Abstract] [Full Text] [Related]
38. AIDS group takes aim at pharmaceutical firm's patents, prices. AIDS Policy Law; 2002 Jul; 17(13):4. PubMed ID: 12162289 [No Abstract] [Full Text] [Related]
39. The consumer welfare implications of governmental policies and firm strategy in markets for medicines. Chatterjee C; Kubo K; Pingali V J Health Econ; 2015 Dec; 44():255-73. PubMed ID: 26581076 [TBL] [Abstract][Full Text] [Related]
40. The shifting functional balance of patents and drug regulation. Eisenberg RS Health Aff (Millwood); 2001; 20(5):119-35. PubMed ID: 11558697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]